Gregory D. Jay, Norfolk, MA (US); Benjamin D. Sullivan, Concord, MA (US); Tannin Avery Schmidt, Avon, CT (US); Khaled Elsaid, Irvine, CA (US); Edward R. Truitt, Medina, WA (US); Roman Krawetz, Calgary (CA); Jawed Fareed, Westchester, IL (US); Joanna Szmydynger-Chodobska, Providence, RI (US); and Adam Chodobski, Providence, RI (US)
Assigned to Lubris LLC, Naples, FL (US); and Rhode Island Hospital, Providence, RI (US)
Filed by Lubris LLC, Naples, FL (US); and Rhode Island Hospital, Providence, RI (US)
Filed on Mar. 8, 2021, as Appl. No. 17/194,747.
Application 17/194,747 is a continuation of application No. 15/546,192, granted, now 10,967,048, issued on Apr. 6, 2021, previously published as PCT/US2016/014952, filed on Jan. 26, 2016.
Claims priority of provisional application 62/273,059, filed on Dec. 30, 2015.
Claims priority of provisional application 62/107,799, filed on Jan. 26, 2015.
Prior Publication US 2021/0299214 A1, Sep. 30, 2021
1. A method of reducing or inhibiting inflammation associated with brain injury in a patient suffering from a brain injury comprising administering proteoglycan 4 (PRG4) comprising the amino acid sequence of residues 25-1404 of SEQ ID NO:1 to said patient, thereby reducing or inhibiting inflammation in the brain associated with the brain injury to treat the brain injury.